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Abstract 
The alternative oxidase (AOX) is a monotopic di-iron carboxylate protein which acts 
as a terminal respiratory chain oxidase in a variety of plants, fungi and protists. Of 
particular importance is the finding that both emerging infectious diseases caused by 
human and plant fungal pathogens, the majority of which are multi-drug resistant, 
appear to be dependent upon AOX activity for survival. Since AOX is absent in 
mammalian cells, AOX is considered a viable therapeutic target for the design of 
specific fungicidal and anti-parasitic drugs.  
In this work, we have mutated conserved residues within the hydrophobic channel 
(R96, D100, R118, L122, L212, E215 and T219), which crystallography has 
indicated leads to the active site. Our data shows that all mutations result in a drastic 
reduction in Vmax and catalytic efficiency whilst some also affected the Km for quinol 
and oxygen. The extent to which mutation effects inhibitor sensitivity was also 
investigated, with mutation of R118 and T219 leading to a complete loss of inhibitor 
potency. However, only a slight reduction in IC50 values was observed when R96 
was mutated, implying that this residue is less important in inhibitor binding. In silico 
modelling has been used to provide insight into the reason for such changes, which 
we suggest is due to disruptions in the proton transfer network, resulting in a 
reduction in overall reaction kinetics. We discuss our results in terms of the structural 
features of the ubiquinol binding site and consider the implications of such findings 
on the nature of the catalytic cycle.  
Significance 
The alternative oxidase is a ubiquinol oxidoreductase enzyme that catalyses the 
oxidation of ubiquinol and the reduction of oxygen to water. It is widely distributed 
amongst the plant, fungal and parasitic kingdoms and plays a central role in 











1. Introduction  
The alternative oxidases (AOX) are important ubiquinol oxido-reductases 
which play a key role as terminal oxidases in the respiratory chains of plants, fungi 
and protists. AOXs are located on the substrate-side of the cytochrome bc1 complex 
and catalyse the oxidation of ubiquinol and the four electron reduction of oxygen to 
water in a non-protonmotive fashion, with the excess energy being released as heat. 
Whilst the function of the protein is organism dependent, it is important to recognise 
that it is a major contributor to reducing cellular levels of reactive oxygen species 
through maintaining the ubiquinone pool in a relatively oxidised state, thereby 
preventing mitochondrial damage [1, 2]. Although thermogenic plants utilise the AOX 
for pollination purposes, [3, 4] all other plant cells and fungal pathogens tend to 
engage the AOX when respiratory activity is hindered either as a result of respiratory 
inhibition [5] or other stresses such as drought [6]. Of particular significance is the 
finding that a number of highly pathogenic protists, such as Trypanosoma brucei [7], 
Cryptosporidium parvum [8], Blastocystis hominis [9] and the microsporidia all 
contain an AOX. Within these organisms, AOX plays a critical role during their 
respective life-cycles, with cases such as the T. brucei utilising the protein as its sole 
terminal oxidase whilst in its bloodstream form [10]. Since the protein is absent from 
mammals it has therefore become a novel therapeutic target for the treatment of 
diseases caused by such organisms [11].  
Furthermore, the emergence of fungal infectious diseases is increasingly recognized 
as not only posing a world-wide threat to food security, but more recently pose a 
major threat to human and ecosystem health. The impacts of fungal diseases are 
clearly seen in cereal crops, such as wheat and rice in addition to maize, potatoes 
and soybean, and more recently emerging fungal infections are devastating world-
wide cacao and banana plantations [12, 13]. In human diseases, in addition to the 
role of AOX in parasites, it also plays a key metabolic role in opportunistic human 
fungal pathogens such as Candida albicans [14], Candida auris (candidiasis), and 
Cryptococcus neoformans (cryptococciosis)[15]. Immunocompromised individuals 
are not only particularly susceptible to infection by such opportunistic pathogens, but 
also to other emerging human pathogens possessing AOX. 
 
Given the important cellular role of the AOX in the metabolism of such organisms, 
the need to control AOX activity is obvious. Ascofuranone is an extremely potent 
inhibitor of the trypanosomal AOX (TAO) [16] but as recently shown by May et al. 
this compound does not inhibit all alternative oxidases [17]. In an attempt to develop 
more species-specific inhibitors, we have investigated the quinone-binding site and 
its role within the catalytic cycle to determine suitable targets. Current predictions on 
the mechanism of oxygen reduction by the alternative oxidases [18] are based on 
the activity of other well defined di-iron proteins such as rubrerythrin [19], methane 
monooxygenase [20] and ribonucleotide reductase [21]. However, the lack of 
spectroscopic handle and the poor solubility of the purified AOX has made detection 
of intermediates, and therefore the determination of the complete catalytic cycle, 
difficult.  
 
Figure 1: Position of the hydrophobic cavity within the AOX dimer. Magenta bulb in the surface diagram 
denotes the entrance. Hydrophobic cavity extending from the membrane between helices 1 and 4 towards the di-
iron core. Insert depicts binding of the protein to the inhibitor colletochlorin B (cyan), with labelled residues 
being discussed within this manuscript. Yellow dotted lines depict the hydrogen bonding network between the 
residues and inhibitor. Coloured atoms are oxygen (Red), nitrogen (Blue) and chlorine (Green). 
Examination of TAO crystal structures co-crystallised with inhibitors [22] have 
revealed a number of key polar residues for inhibitor binding that line the 
hydrophobic cavity leading from the membrane towards the di-iron core (Figure 1), 
namely R96, D100, R118, E215 and T219. Previous examination of sequence 
alignments [18] has shown that these amino acids are almost all fully conserved 
across all AOX’s, with the exception of T219, which is a replaced by serine in select 
plant and fungal species [23]. These conserved residues can largely be divided up 
into two sub-groups; R96, R118, and T219, which all bind directly to the inhibitor via 
hydrogen bond formation, whereas D100 and E215 provide structural support to the 
former group of amino acids. The remaining highlighted residues, L122 and L212, 
form a hydrophobic bottleneck within the cavity, which we have previously proposed 
ensure the correct orientation of the substrate during its entry into the active site [24].  
In this study we investigated the role of these amino acids (R96, D100, R118, L122, 
L212, E215 and T219) on substrate binding and oxygen reduction through the 
generation of residue specific mutations in recombinant TAO expressed in 
Escherichia coli. Each of these mutants were purified and assayed to assess the role 
of these residues on the overall reaction kinetics for both quinol and oxygen. We 
demonstrate that each of the mutations are critical for enzymatic activity, reducing 
the catalytic efficiency by approximately 95% in all cases. However, whilst the Km for 
quinol was reduced for all the mutations that interact directly with the substrate, 
importantly no change in quinol Km for the E215 variants were observed. Analysis of 
the Km for oxygen revealed that mutational effects were minimal, confirming that 
reduction in the overall Vmax is due to a structural impairment in quinol binding within 
the active site. In silico modelling suggested that the reason for such dramatic 
changes in kinetic properties is undoubtedly due to disruptions in the proton transfer 
network thereby resulting in a disruption of the catalytic cycle. Such studies have 
provided us with structural information on the binding of quinol within the active site 
of AOX which will be important in the subsequent design and development of potent 




2. Materials and methods 
2.1. Plasmid preparation and generation of mutants 
The design of rTAO was based on the Trypanasoma brucei brucei sequence 
(GenBank accession number: AB070617.1). Gene constructs were designed to 
introduce amino acid substitutions (residues as stated in the main text) and were 
synthesized with codon optimization for expression in E. coli. Constructs contained 
NdeI and BamHI restriction endonuclease sites at 5’ and 3’ ends respectively, for 
insertion into the pET-15b expression vector (Genscript, Piscataway, NJ). 
 
2.2.  Preparation of membrane samples 
The E. coli strain FN102(DE3) carrying the previously described pET-15b 
vectors containing cDNA for TAO, or subsequent mutant sequences, were pre-
cultured at 37°C in L-broth [containing 100 μg ml-1 5-aminolevulinic acid (ALA), 50 μg 
ml-1 ampicillin, 50 μg ml-1 kanamycin] for 4 hours. Cells were then collected by 
centrifugation at 7,000g for 15 min, with the subsequent pellet washed twice with L-
broth to remove excess ALA. The pre-cultured cells were transferred into growth 
medium containing 40 g peptone, 20 g yeast extract, 20 g casamino acid, 41.6 g 
K2HPO4, 2.9 g trisodium-citrate, 10 g (NH4)2SO4, 0.2 g MgSO4, 0.1 g FeCL3, 0.1 g 
FeSO4, 0.2% (w/v) glucose, and 0.4 g carbenicillin. The culture was then initiated at 
OD600= 0.01 at 30°C and expression of rTAO (and mutants) was induced by the 
addition of isopropyl β-D-1-thiogalactoside (IPTG) (25 µM) at OD600 = 0.6. Cells were 
harvested 12 hours following induction and were resuspended in 50 mM Tris-HCl 
(pH 7.5) containing protease inhibitor cocktail (Sigma) and broken by a French 
Pressure Cell at 10 kPa. Unbroken cells were removed by centrifugation at 10,500g 
for 15 min. E. coli membranes were collected by ultracentrifugation at 200,000g for 1 
hour at 4°C. The membrane pellet was resuspended in 50 mM Tris-HCl (pH 7.5) to 
an approximate protein content of 12 mg ml-1.  
Protein content was estimated using the Bradford method [25], with the Bio-Rad 
protein assay dye using BSA as a standard.  
 
 
2.3. Protein Solubilisation and Purification Techniques 
Membranes were treated with solubilisation buffer (6 mg ml-1 protein in 50 mM 
Tris-HCl, 1.4% (w/v) n-octyl-β-D-glucopyranoside (OG), 200 mM MgSO4, 20% (v/v) 
glycerol, pH 7.3) at 4°C for 1 h. The sample was then centrifuged at 200,000g for 1 h 
at 4°C, and the insoluble pellet was subsequently discarded.  
Hybrid batch/column procedure described in manufacturer’s instruction was used as 
stated below. 1 mL of resin (BD Bioscience, TALON Metal Affinity Resin) was 
equilibrated in a batch format by 10 mL of equilibration buffer (20 mM Tris-HCl, 1.4% 
(w/v) OG, 100 mM MgSO4, 20% (v/v) glycerol pH 7.3). Two millilitre of solubilised 
protein was mixed with the resin for 20 min at 4°C. The resin was washed twice with 
10 mL of wash buffer [20 mM Tris-HCl, 20 mM imidazole, 0.042% (w/v) n-dodecyl-β-
D-maltopyranodise (DDM), 50 mM MgSO4, 20% (v/v) glycerol, pH 7.3]. The rTAO 
was eluted with elution buffer [20 mM Tris-HCl, 250 mM imidazole, 0.042% (w/v) 
DDM, 50 mM MgSO4, 60 mM NaCl, 20% (v/v) glycerol, pH 7.3].  
 
2.4. Measurement of Quinol and Oxygen Kinetics  
Kinetic analysis of purified rTAO was performed spectrophotometrically using 
Cary 400 UV spectrophotometer with the packaged software. All assays were 
performed using a quartz 1 cm cuvette with 1 ml 50mM Tris-HCl pH 7.4, 0.02% EDT-
20, measuring the conversion of Q1H2 (ubiquinol-1) to Q1 (ubiquinone-1) at 278 nm 
(Ɛ = 15, 000 M-1 cm-1). Q1 was reduced to Q1H2 prior to experimentation via 
sonication with zinc powder under an inert atmosphere for ~10 minutes, with the 
resultant zinc removed via centrifugation at 2000 x g.  
Results were fit to Michaelis-Menten plot via a least squared method 
using GraphPad Prism version 7.0 for Windows, GraphPad Software, La Jolla 
California USA, www.graphpad.com. 
Oxygen kinetics were obtained polarographically using a rank type oxygen electrode. 
E. coli membrane fractions were added to 2 ml 50 mM Tris-HCl pH 7.4 with 1 mM 
KCN and the reaction was initiated with the addition of 1.25 mM NADH. An oxygen 
consumption rate of ~1 nmol O2 min-1 mg-1 was sufficient to allow enough data points 
to be collected for determination of O2 Km via an Eadie-Hofstee graph.   
2.5. Inhibitor dose response  
Inhibitors were tested in a 96-well plate format. E. coli membrane samples 
containing the appropriate AOX were diluted to ~ 60 µg ml-1 in 50 mM Tris-HCl (pH 
7.5) containing 1 mM KCN. All inhibitors were dissolved in DMSO and added to the 
wells to a final concentration of 0.1% (v/v) DMSO. Respiration was initiated with an 
addition of 0.3 mM NADH and the reaction was tracked at 340 nm for 10 minutes using 
a ThermoscietificTM Multiskan Sky and packaged SkanIt 5.0 software. Dose response 
curves were plot using the least squared method in graphpad, with all data being 
shown as an average of 3 separate preparations ± SEM.  
 
2.6. Computational Methods 
The TAO protein structure (PDB:3W54) was loaded into MOE software 
(Molecular Operating Environment, version 2016.08, Chemical Computing Group Inc., 
Montreal, Canada) for some preparatory steps to correct any structural issues. Hence, 
the hydrogen bond network was optimised using the Protonate 3D algorithm and 
AMBER99 forcefield was used in assigning correct electronic charges. Mutations were 
then subsequently generated, followed by sequential local energy minimization and a 
full system minimization using the AMBER99 forcefield. 
The 3D structure for Q2H2 (ubiquinol-2) was built within MOE and energy 
minimized using the Amber10: EHT forcefield. A second minimization was applied 
using the MOPAC semi-empirical energy functions (PM3 Hamiltonian).  
Q2H2 was docked into the binding site of the AOX using the Triangle Matcher 
placement method with London dG scoring. Subsequently, poses resulting from the 
placement stage were further refined using the Induced Fit method, which allows 
protein flexibility upon ligand binding, improving the prediction accuracy for the 
interaction. Poses were rescored using the GBVI/WSA dG scoring function and the 




2.7.  Materials 
All reagents were purchased from Sigma-Aldrich unless otherwise stated. Of 
the inhibitors tested, samples of ascochlorin and ascofuranone were kindly provided 
by Professor Saimoto (Tottori University) Colletochlorin B and D was synthesised in 
house using previously published methods [26]. 
2.8.   Statistical analysis 
All statistical analysis was performed in GraphPad prism 7.0. Where quoted, all 
averages displayed are a mean average of 3 replicates ± SEM. Where relevant, p 
values were determined using a 1-way ANOVA test, with comparisons being made to 



















3.1  Recombinant protein expression 
Recombinant wild type and mutant rTAO protein was obtained from heme-
deficient E. coli membrane fraction and purified via cobalt affinity chromatography as 
described within in Materials and Methods, which we have previously shown to be 
effective at generating stable purified rTAO [27]. Purity of the protein was assessed 
via SDS-gel and western blot analysis, with each preparation giving a single band at 
~32 kDa (data not shown).  
 
 
Figure 2: A) Example quinol oxidation trace for purified rTAO. ↓ denotes addition of Q1H2 and purified rTAO 
protein to allow for determination of auto-oxidation rate and protein Q1H2 consumption rate respectively. B) 
Michaelis-Menten graph for purified rTAO. Analysis was performed in 1 ml of Tris-HCl pH 7.4 with Q1H2 
concentrations varied between 10-500 μM. Values were determined by fitting the data to a Michaelis-Menten 








(μmol Q1H2 min-1 mg-1) 
Vmax  
(% of wild-type) 
Catalytic 
efficiency (s-1 M-1) 
Wild-type 270 ± 28 100 9.18 x 105 ± 0.3 
R96A 4.32 ± 3.1 1.6 ± 1.1 1.16 x 105 ± 0.3 
R96K 5.39 ± 3.2 2.0 ± 1.2 1.17 x 105 ± 0.5 
D100A 2.48 ± 1.1 0.9 ± 0.4 1.04 x 105 ± 0.3 
D100E 4.16 ± 2.2 1.5 ± 0.8 1.62 x 105 ± 0.4 
R118A 5.85 ± 0.9 2.1 ± 0.3 4.08 x 104 ± 1 
R118K 9.59 ± 3.5 3.6 ± 1.3 4.66 x 104 ± 1 
T219A 3.57 ± 1.4  1.3 ± 1.0 2.52 x 104 ± 0.7 
T219S 1.41 ± 0.3 0.5 ± 0.1  1.03 x 104 ± 0.1 
L122A 2.47 ± 1.7 0.9 ± 0.6 2.67 x 104 ± 1 
L212A 4.20 ± 0.2 1.5 ± 0.1 2.94 x 104 ± 0.7 
E215A 8.08 ± 1.9 2.9 ± 0.7 2.70 x 104 ± 0.02 
E215D 0.68 ± 0.6 0.2 ± 0.2 1.74 x 103 ± 0.9 
E215N 0.49 ± 0.04 0.2 ± 0.0 1.62 x 103 ± 0.02 
Table 1: Vmax and catalytic efficiency values determined for purified wild type rTAO and mutants, using the 
method outlined in figure 2. All data presented as an average of 3 measurements ± SEM. 
Kinetic analysis of the purified protein was performed by measuring the rate of Q1H2 
oxidation at 278 nm, with the determined rates subsequently plotted in a Michaelis-
Menten graph as depicted in Figure 2. The selected residues were initially mutated to 
alanine to assess the importance of each side-chain to the overall reaction kinetics, 
and as can be seen in Table 1, each alanine substitution resulted in over 95% 
reduction in Vmax when compared to wild-type. Further secondary mutations were 
generated based on retention of function of the initial side-chain, with selection being 
made for keeping the same charge (R96K, R118K and T219S) or complete retention 
of the carboxylate functionality but with a modification in side-chain length (D100E and 
E215D). It is apparent from Table 1 that some secondary mutations appeared to 
partially restore catalytic activity. For instance R96K, D100E and R118K all show a 
slight increase in catalytic activity over their alanine counterparts, whereas T219S and 
E215D/N show a further decrease in their respective Vmax values, suggesting they are 
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Figure 3: A) Effects of mutation upon the Km for quinol. B) Catalytic efficiency of mutants. rTAO wild-type 
omitted for clarity, giving a value of 9.2 × 105 ± 0.3 s-1. 
 
As is apparent from Figure 3, there is a significant change (p=0.0001) in the Km for 
Q1H2 for all mutations, with the exception of the E215 mutations. Of the three residues 
that bind directly to quinol, T219A/S shows a significantly less pronounced reduction 
in Q1H2 Km values when compared to R96 and R118 mutations. Whilst the crystal 
structures of TAO indicate that D100 does not interact directly with the inhibitor 
(PDB:3w54 [22]), and therefore the substrate, the reduction in Km value would suggest 
that its role in structurally supporting both R96 and R118 is important for quinol binding, 
as the Km value is reduced to a similar extent. As observed with Vmax, secondary 
mutations do not significantly alter the Km for quinol when compared to their alanine 
counterparts. 
Given the large reduction in Vmax and Km for each mutation, calculation of the catalytic 
efficiency (defined as Kcat/Km) allows for clearer comparison of the mutation effect 
upon the overall activity as it takes into account changes to both the Vmax and the KM 
values. Using this metric it is apparent that the mutation of both R96 and R118 are 
considerably less detrimental then the other mutants, reducing catalytic efficiency to 
1.2 x 105 ± 0.3 s-1 (R96A) and 1.1 x 105 ± 0.2 s-1 (R118A) respectively from 9.2 x 105 ± 
0.3 s-1 for the wild type. Given the positioning of the quinol OH between R96, R118 
and T219, we can infer that the interaction with T219 is the most important of the three 
when it comes to catalytic activity, suggesting that both R96 and R118 fulfil a similar 
role in stabilising the orientation of the quinol OH, with both residues being necessary 
to position the OH towards T219. 
What was surprising, however, was the result that E215D/N mutations have the largest 
effect on the catalytic efficiency, suggesting that whilst they are not directly involved in 
the binding of the substrate, they must perform a critical role in the catalytic cycle. It is 
also worth noting that the catalytic efficiency of the secondary mutations were 
considerably lower than their alanine counterpart, with the E215D and E215N mutants 
possessing values of 1.7 x 104 ± 0.9 s-1 and 1.6 x 104 ± 0.1 s-1 M-1 respectively, an 
order of magnitude lower than their E215A counterpart which has a  catalytic efficiency 



















3.2  Oxygen Kinetics 
 
The Km for oxygen was determined in the same manner as previously used for 
recombinant Saromatum guttatam AOX and mutants [24]. Recombinant rTAO grown 
in the heme-deficient E. coli strain is responsible for ~98% of total oxygen consumption 
with the remaining 2% being attributed to cytochromes bd/bo activity. In the presence 
of an excess of NADH within these assays, any loss of respiratory activity following 
the establishment of steady state kinetics can be attributed solely to the reduction in 
the concentration of oxygen within the chamber, with the relationship between oxygen 
concentration and respiratory rate obeying standard Michaelis-Menten kinetics. This 
















































































Figure 4: - Oxygen Km values determined using method described figure 4 Data is an average of 3 replicates +/- 
SEM. Numerical values can be found in the Appendix Table 1.  
The data in figure 4 demonstrates that a majority of these mutations have little effect 
on the Km for oxygen, with only R96A/K (p=0.0081 and 0.0003), R118A (p=0.0161) 
E215D (p=0.0001) altering the Km with any statistical significance. Both R96A/K 
mutations have a lower Km value, whereas only R118A and E215D show any effect 
on the oxygen Km within their respective amino acid substitutions, implying that these 
two amino acid substitutions are more deleterious to oxygen binding than simply 
removing the amino acid side chain. It is Interesting to note that the D100 mutations 
did not alter the oxygen Km, which is in contrast to previous results obtained with the 
analogous mutation in the Sauromatum guttatum rAOX [24].  
3.3 Mutant Inhibitor dose response  
 
In order to further assess the impact of mutations within the quinol binding site, 
dose response curves were determined using a range of AOX inhibitors. Of those 
tested, octyl-gallate (OG) and Salicylic hydroxamic acid (SHAM) are classic inhibitors 
of AOX with relatively low inhibitory efficacy, with the remaining 4 compounds being 
quinol mimetic inhibitors which are believed to be transition state analogues for quinol 
[28]. 
 
Mutation AC AF CB CD OG SHAM 
Wild-type 7.4 ± 3 7 ± 5 7.5 ± 1 33 ± 5 230 ± 6 6.1 µM 
R96A 167 ± 55 58 ± 24 470 ± 225 1.54 ± 0.3 µM  46 ± 25 µM 22 µM 
R96K 316 ± 96 129 ± 30 66 ± 25 51 ± 5 2.3 ± 1.5 µM 4.4 µM 
D100A 203 ± 14 51 ± 5 137± 18 81 ± 16 308 ± 45 4.4 µM 
D100E 221 ± 19 89 ± 14 139± 11 90 ± 15 5.2 ± 1.1 µM 3.7 µM 
R118A NI NI NI NI NI NI 
R118K NI NI NI NI NI NI 
T219A NI NI NI NI NI NI 
T219S NI NI NI NI NI NI 
L122A NI NI NI NI NI NI 
L212A 215 ± 22 38 ± 4 36 ± 8 61 ± 15 862 ± 120 4.7 µM 
E215A NI NI NI NI NI NI 
E215D NI NI NI NI NI NI 
E215N NI NI NI NI NI NI 
 
Table 2: IC50 values for AOX inhibitors against each membrane bound mutation. Compounds tested are as 
follows: Ascochlorin (AC), Ascofuranone (AF), Colletochlorin B (CB), Colletochlorin D (CD), Octyl-gallate 
(OG) and Salicylic hydroxamic acid (SHAM).  All values denoted are in nM and displayed as an average of 3 
repeats ± SEM. NI indicates an IC50 >50µM. 
 
As is apparent from Table 2, there is a distinct split in effects on inhibitor efficacy. 
Mutation of R118 and T219, two of the residues that interact directly with colletochlorin 
B in the crystal structure [22], lead to a complete loss of inhibition. However, there is 
only a slight reduction in IC50 values when R96 is mutated, which implies that this 
residue is less important to the binding of the inhibitor than we previously thought. With 
respect to the leucine residues, mutation of L122 is clearly more detrimental when it 
comes to inhibition, although whether this is due to reduction in binding efficacy of the 
compound or alteration to the pocket shape remains to be determined. What was 
surprising, however, was the complete lack of inhibition with respect to the E215 
mutations, given that they are not directly involved in inhibitor binding.  
 
 
3.4 Substrate docking 
 
 
Figure 5: Docking studies for Quinol (magenta) and Quinone (cyan) within the TAO crystal structure 
(PDB:3W54). Yellow dotted lines denote potential hydrogen bond formation (distance less than 3.5 Å) between 
quinone species and residues within the cavity, and the green dotted line denotes the increased 4.5 Å from R96 
to the substrate.  
 
In order to ensure that the residues responsible for inhibitor binding are also all 
involved in substrate binding, docking of quinol was performed on the crystal 
structures. Whilst the natural substrate for TAO is Q10H2, Q2H2 was used for docking 
purposes as the longer isoprene tail extended out of the hydrophobic cavity (which, 
under physiological conditions would pass into the phospholipid bilayer within 
mitochondria) and hence resulted in erroneous binding along the outside of the 
protein, artificially improved the binding score. Figure 5 shows the lowest ∆Gbind (z=-
8.7 kcal mol-1) that was obtained with Q2H2, with the formation of hydrogen bonds 
between OH-2 and the iron ligating OH/H2O (3.1 Å) and OH-5 bonding to T219 (2.6 
Å) and R118 (3.0 Å). The distance to R96 has increased to from 3.5 Å for the bound 
Colletochlorin B within the crystal structure to 4.5 Å for the docked quinol, indicating 
that while it is an important hydrogen bond donor for the inhibitors, it is not likely to be 
involved directly with substrate binding.   
To ensure that the changes in apparent substrate Km were not due to changes in 
product binding, quinone was also docked, and as can be seen in Figure 5 both 
compounds are able to bind effectively into the active site in its current configuration, 
with quinone demonstrating a slightly higher ∆Gbind than quinol (z= -9.2 kcal mol-1). 
Whilst this is the case for the protein in its current protonation state, it should be noted 
that when quinone is generated as a product of the oxidation reaction, the protonation 













Mutation Quinol binding 
∆Gbind (kcal mol-1)  
Quinone binding 
∆Gbind (kcal mol-1) 
Ratio 
Quinol/Quinone 
Wild-type -8.7 ± 0.1 -9.2 ± 0.2 0.95 
R96A -8.6 ± 0.3 -8.9 ± 0.2 0.96 
R96K -8.8 ± 0.1 -9.0 ± 0.2 0.98 
D100A -8.8 ± 0.2 -9.1 ± 0.1 0.97 
D100E -8.7 ± 0.1 -9.1 ± 0.2 0.95 
R118A -8.3 ± 0.2 -8.4 ± 0.3 0.98 
R118K -8.5 ± 0.2 -8.8 ± 0.1 0.96 
T219A -6.7 ± 0.1 -6.8 ± 0.1 0.98 
T219S -6.6 ± 0.2 -7.3 ± 0.4 0.91 
L122A -8.0 ± 0.1 -8.2 ± 0.2 0.96 
L212A -7.4 ± 0.1 -7.1 ± 0.1 1.05 
E215A -7.6 ± 0.6 -7.5 ± 0.2 1.00 
E215D -6.6 ± 0.1 -6.8 ± 0.1 0.97 
E215N -6.7 ± 0.1 -7.0 ± 0.2 0.96 
 
Table 3: Docking scores determined for quinol and quinone against energy minimised point mutations generated 
within the MOE software. Each score given is an average of the top 3 poses ± standard deviation.   
 
The mutants were then generated from the crystal structure and energy minimised, 
with both Q2 and Q2H2 subsequently docked to investigate the effects on substrate 
binding. All docked compounds were checked manually and found to adhere to similar 
binding positions as the inhibitor determined in the wild-type crystal structure. As can 
be seen in Table 3, most of the mutations generated did not affect the ability of the 
substrate to bind to the protein, with only the mutations of T219, L212 and E215 being 
significantly different to that of the wild type.  
The ratio of Q2 to Q2H2 docking scores were also determined and found not to vary 
wildly from the 0.96 determined for the wild-type. Such data would indicate that whilst 
there are large changes in the apparent Km determined experimentally, this is unlikely 





The ubiquitous nature of the AOX throughout fungal pathogens and its central role 
within cellular homeostasis within these organisms has highlighted a need to develop 
specific AOX inhibitors for the use alongside traditional fungicidal treatment. Whilst the 
ascofuranone analogues investigated within this manuscript are extremely potent, only 
ascofuranone is specific for the AOX, with the other compounds also inhibiting the 
cytochrome bc1 complex [29]. Albeit that such results indicate ascofuranone as the 
clear lead compound, the lengthy and costly synthesis precludes chemical synthesis 
[30], however generation of these compounds using the biosynthetic pathway has 
become a more viable option [31]. 
We have started to probe the mechanism of action of the AOX, with the primary focus 
to understand the catalytic cycle in order to allow for the development of ‘suicide 
inhibitors’ for the AOX, which would reduce the undesired interactions with the 
cytochrome bc1 complex if they are tuned to specific intermediates in the AOX’s 
catalytic cycle. Elucidation of the TAO crystal structure has allowed for a more detailed 
picture of the active site, and we have suggested a number of potential mechanisms 
based on this information [28, 32]. A previous study using FTIR [33] has confirmed 
that the fully oxidised di-iron core reacts with 2 molecules of quinol in a sequential 
manner, and we are working under the assumption that the crystal structure exists as 
the oxidised form of the protein, due to the crystal being obtained under non-reducing 
conditions. Within this study, we have utilised mutagenesis to investigate the reaction 
sequence upon binding of the first quinol within the hydrophobic cavity in order to 
narrow down the roles for each of the residues suggested to be involved in inhibitor 
binding from crystallography.  
While the size and shape of the hydrophobic cavity varies between species [17], the 
majority of the polar residues which line the cavity are conserved throughout the AOX 
family. Given the importance of polar residues for binding and proton transfer, and the 
lack of other potentially reactive residues within the cavity, we are working under the 
assumption that there is a universal catalytic mechanism throughout the AOXs. What 
is clear from the outset of these results is that each of the residues selected for 
mutation are extremely important to overall activity, with each amino acid substitution 
causing at least a 95% reduction in the Vmax (Table 1). However, with the exception of 
R96/118 and E215D, there are no significant changes in the oxygen reaction kinetics 
(Figure 4), which would suggest that the overall structure of the protein is intact, and 
that di-iron core is in the correct conformation to react with oxygen. This would also 
confirm that the reaction of the fully reduced protein with oxygen and quinol are 
completely separate events which do not require either of the molecules of quinol to 
facilitate the binding of oxygen as there are limited changes to the oxygen kinetics 
whilst the Km for quinol is altered in almost all cases. Moreover, when the models for 
quinol docking into the mutants were generated and minimised, negligible changes to 
the overall structure outside of the amino acid side chain were detected.   
With respect to the changes in O2 Km for R96/118, given the distance of these residues 
from the oxygen reactive iron centre, and the lack of perturbation observed around the 
primary ligation sphere in the protein modelling, it is unlikely this has been caused by 
changes in reactivity between oxygen and the di-iron core. We hypothesise this 
apparent change in Km is caused by an increase in solvent accessibility into the 
hydrophobic cavity via an opening that is visible in the protein surface during the 
molecular modelling, allowing oxygen to diffuse more freely into the di-iron core, 
increasing localised O2 concentration and artificially improving the apparent O2 Km. 
With E215D being the only mutation of E215 to affect oxygen kinetics, it is likely that 
this is due to distortion of the position of R96 and opening a similar pore in the proteins 
surface. It would therefore follow that any changes in the overall reaction kinetics are 
predominantly due to changes in reactivity between the protein and quinol. 
In isolation, the lowered Km values for quinol observed in the mutants would imply a 
higher affinity for quinol, and therefore an increase in overall activity would be 
anticipated. This is clearly not the case, as the Vmax has dropped considerably in all 
cases and the docking scores (Table 3) show minimal changes. Given that the 
reduction in Vmax may have artificially reduced the quinol Km value, the catalytic 
efficiency was calculated since it provides a less biased metric on the effects of each 
mutation. Figure 3 clearly demonstrates that all mutations result in a reduction in the 
overall reaction kinetics, since all possess a catalytic efficiency significantly lower than 
the wild type.  
What is clear from the inhibition studies (Table 2) is that there is a significant split in 
the importance of residues with respect to inhibitor binding. R96, D100 and L212 
reduce inhibitory efficacy by 5-40 fold, whereas all other mutations led to a complete 
loss of efficacy. However, the docking studies demonstrated that while these residues 
are important for inhibitor binding, only mutations of T219, L212 and E215 significantly 
altered the binding ability of the substrate. Given that it has recently been suggested 
that the ascofuranone family of compounds behave as transition state analogues [28], 
which in the case of AOX turnover would likely constitute a semi-quinone radical, we 
propose the following roles for each residue based on the data collected within this 
study: 
Since L212A reduced the binding efficacy of the substrate but the reduction in 
inhibition was relatively small, we suggest that the reduction in Vmax can be attributed 
to a reduced substrate binding affinity. However, mutations of R96 and D100 had no 
effect on the docking score and only a slight reduction in inhibitor potency, suggesting 
that the reduction in catalytic activity is not due to binding affinity but more likely to be 
mechanistic or structural in nature.  
The remaining residues, R118, L122 and T219, resulted in a complete eradication of 
inhibitor potency, implying they are involved with keeping the semiquinone radical 
bound during the transition state. This is inline with recent protein ligand interaction 
fingerprint (PLIF) experiments, which suggested that these are the most important 
residues when it comes to inhibitor interactions, and are therefore the most likely 
candidates to be stabilising the semi-quinone intermediate [34]. However, only the 
T219 mutants altered the docking score as well, indicating it is the only residue that 
fully interacts with both the substrate and its transition state.    
 
 
Figure 6: The two proposed routes for the proton relay pathway, with water molecules indicating the aqueous 
environment. Green Residues are common in both pathways, with red denotes the D100 pathway predicted in 
[32] and blue is the pathway predicted by Shiba et al. [28]. R118 has been omitted for clarity.  
 
T219, R96, R118, E215 have also been proposed to be involved in an additional role 
in quinol oxidation, namely in the provision of a proton relay pathway to solvent (Figure 
6) [28, 32]. We would suggest that D100 also plays a role within this network given the 
lack of any effects on either the docking or inhibition studies. There is, however, a 
potential catalytic redundancy between R96 and R118, as both offer routes of egress 
for a proton away from the active site. R96 is bound to both E215 and D100, which 
are both solvent facing residues, whereas R118 is only bound to D100. Energy 
minimisation of the protein revealed that whilst the crystal structure shows D100 is 
bound in a bidentate form, it is fully capable (and arguably energetically favourable) to 
bridge the R96 – R118 distance in a monodentate fashion, as depicted in Figure 7. 
Whilst purely speculative at this point, this relative freedom of movement would allow 
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Figure 7: Molecular modelling of the hydrogen bonding network for Wild-type TAO and mutants. 
Coloured atoms are oxygen (red), nitrogen (blue) and hydrogen (white), where heteroatoms joined by 
a white line denote species which are close enough for hydrogen bond formation between the pair. 
L122/212 not included as they showed no effect on the proton transfer network.  
If this proposal is correct, and the breakdown of the proton transfer network is 
responsible for the reduction in overall reaction kinetics, it would explain why the 
mutation of E215 has such a large effect on the overall activity whilst not effecting the 
Km for quinol. Figure 7 shows putative proton transfer networks, and as can clearly be 
seen, all mutations lead to a breakdown of the network, with the exception of the E215 
mutations. This lack of network breakdown, with particular focus of the T219-R96 
hydrogen bond, would leave the binding to quinol unaffected. The change in residue 
would still lead to a change in electronic effect throughout the network, potentially 
reducing the networks ability to shuttle protons from the active site. However, given 
the abundant nature of protons within an aqueous solution, this would be extremely 
difficult to establish experimentally. It should also be noted that the terminus of the 
proton transfer network for both E215D and E215N point back into the protein instead 
of out to solvent, providing a further barrier for proton egress from the system.    
In conclusion, we have mutated residues within the hydrophobic cavity of the 
trypanosomal AOX which crystallographic studies identified as being key for substrate 
and inhibitor binding. Amino-acid sequence analysis of all published AOX proteins 
revealed that these residues were totally conserved suggesting they are essential for 
substrate-binding. Measurement of catalytic activity confirmed the essentiality of these 
residues since every mutation resulted in a loss of >95% activity in comparison to the 
wild-type. Furthermore, such mutations also result in a substantial decrease in inhibitor 
efficacy. Whilst it would be extremely difficult to predict potential mutations in vivo, 
which could generate resistance to these compounds, this study has demonstrated 
that inhibitors that target the polar residues within the hydrophobic cavity are highly 
unlikely to lead to the generation of AOX proteins which are resistant to the inhibitor 
whilst retaining functionality.  
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Mutation Km Q1H2 (µM) Catalytic efficiency 
(s-1 M-1) 
Km Oxygen (µM) 
Wild-type 339.0 ± 16 9.18 x 105 ± 0.3 13.6 ± 1 
R96A 48.8 ± 19 1.16 x 105 ± 0.3 8.1 ± 1 
R96K 61.3 ± 12  1.17 x 105 ± 0.5 6.2 ± 2 
D100A 78.2 ± 13 1.04 x 105 ± 0.3 15.3 ± 1 
D100E 121.7 ± 26 1.62 x 105 ± 0.4 14.8 ± 1 
R118A 78.3 ± 30 4.08 x 104 ± 1 8.5 ± 0.5 
R118K 68.0 ± 2 4.66 x 104 ± 1 15 ± 2 
T219A 113.3 ± 27 2.52 x 104 ± 0.7 13.4 ± 1  
T219S 169.7 ± 35 1.03 x 104 ± 0.1 17.3 ± 2 
L122A 146.3 ± 32 2.67 x 104 ± 1 16.8 ± 1 
L212A 170.3 ± 50 2.94 x 104 ± 0.7 14.7 ± 1 
E215A 337.4 ± 50 2.70 x 104 ± 0.02 12.9 ± 1 
E215D 429.5 ± 24 1.74 x 103 ± 0.9 5.5 ± 0.5 
E215N 347.3 ± 15 1.62 x 103 ± 0.02 12 ± 1 
 
Table 1: Numerical values for the kinetic properties of rAOX TAO wildtype and mutants 
discussed in the main body of the text. All values are an average of 3 replicates ± 
SEM. 
